Although inflammation is a necessary biological process in response to injury and disease, at abnormal levels it is also responsible for a significant annual health burden. Immune-mediated inflammatory disease is present at a prevalence of about 7% in the Western world and with an ever aging population this is set to rise. While treatments for some of the more common inflammatory disorders such as rheumatoid arthritis (RA) do exist, there is still a large unmet patient need as many sufferers do not achieve remission of symptoms even when using currently available therapies. Immuno-inflammation is one of GlaxoSmithKline (GSK)'s key therapeutic areas of interest. Helen Albert speaks to Paul-Peter Tak, Senior Vice President and Chief Immunology Officer at GSK, about his career and the work he is doing at GSK to encourage scientific innovation and target unhealthy inflammation in all its forms.
Feature| August 01 2017
Targeting immuno-inflammation: where industry and academia interface
Biochem (Lond) (2017) 39 (4): 38–41.
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
Targeting immuno-inflammation: where industry and academia interface. Biochem (Lond) 1 August 2017; 39 (4): 38–41. doi: https://doi.org/10.1042/BIO03904038
Download citation file: